Company

About

Aiosyn

Aiosyn

Nijmegen, Netherlands

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

Enpicom

Enpicom

Amsterdam, Netherlands

ENPICOM is an innovative bioinformatics software engineering company committed to accelerating biologics discovery and development through cutting-edge bioinformatics solutions. With a deep understanding of biology, software engineering, and AI, ENPICOM delivers innovative tools that empower scientists to make groundbreaking discoveries faster and more accurately. For more information visit enpicom.com.

Thirona

Thirona

Toernooiveld 300, Nijmegen, 6525 EC, NL

Thirona is a global company based in Nijmegen, the Netherlands, that specializes in AI-powered medical image analysis, focusing on lung and retina images. Founded in 2014, Thirona combines medical science with artificial intelligence to deliver advanced solutions for clinical trials, treatment development, and personalized patient care. The company offers high-precision quantitative analysis of medical images, including lung quantification software that analyzes chest CT scans for lung disease detection and treatment planning. Their services also include the quantification of anatomical volumes, mapping of parenchymal disease distributions, and analysis of airway and vascular morphology. In addition to lung analysis, Thirona provides retina image analysis solutions, such as iCare RETCAD, which detects conditions like diabetic retinopathy and glaucoma. Thirona collaborates with clinical research organizations, multinational MedTech companies, and professionals in interventional pulmonology, supporting over 600 clinical sites in more than 40 countries and contributing to over 200 scientific papers.